KAPA Stock Catalyst: Kairos Pharma Reports Positive Interim Efficacy Data from Phase 2 Trial of ENV-105

Oct 6, 2026 · 7:30am ET

Company announced statistically significant results in metastatic prostate cancer treatment.

Max move

+38.0%

High of day $2.13

Sparker timei

7:30am ET

KAPA · Oct 6, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Kairos Pharma, LTD. (NYSE: KAPA) announced on October 6, 2026, positive and statistically significant interim efficacy data from its Phase 2 trial of ENV-105 in patients with metastatic prostate cancer. The trial demonstrated promising results in treating the condition.

The announcement was made via an 8-K filing with the SEC, detailing the interim efficacy data. The company did not provide specific numerical data in the announcement.

As of the latest company context, Kairos Pharma has a free float of 1,281,170 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time KAPA sparks.

Download Sniper App →

Catch the next KAPA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →